双能CT碘定量与常规衰减测量在鉴别小真性强化肾肿块与高衰减非强化肾病灶中的比较
本研究纳入220例患者共265个高衰减肾病灶(91个强化病灶),比较双能CT碘定量与常规衰减变化测量鉴别强化与非强化病灶的诊断准确性,以病理、其他影像确认或>24个月随访为参考标准。常规衰减变化测量的AUC为0.973,显著高于碘定量的0.875(p<0.0001);采用平台特异性优化阈值后碘定量AUC仅 marginal 提升至0.907(快速kV切换平台)和0.893(双源平台)。结论认为碘定量诊断准确性劣于常规衰减变化测量。
要点
- 常规衰减变化测量鉴别强化与非强化高衰减肾病灶的AUC为0.973,优于碘定量的0.875(p<0.0001)。
- 碘定量采用平台特异性优化阈值后AUC仅轻度提升:快速kV切换平台0.907,双源平台0.893。
- 平扫病灶衰减值(p=0.0010)和肾实质内位置(p=0.0249)显著影响碘定量技术的诊断准确性。
核心结论
- 双能CT碘定量鉴别小真性强化肾肿块与高衰减非强化肾病灶的诊断准确性劣于常规衰减变化测量。
研究设计与样本
- 研究纳入220例非连续患者(平均年龄66±13岁,男130例、女90例)共265个高衰减肾病灶(平均衰减54±33 HU,其中91个强化病灶),每例患者行单能平扫CT后于肾实质期行双能CT,使用四种高端双能CT平台之一(第一代和第二代快速kV切换双能CT平台、第二代和第三代双源双能CT平台),以病理分析、其他影像学模态确认或大于24个月的影像随访作为参考标准。
诊断标准与关键数值
- 常规衰减变化测量鉴别强化与非强化肾病灶的AUC为0.973,碘定量测量AUC为0.875(p<0.0001);采用平台特异性优化碘定量阈值后,快速kV切换双能CT平台AUC为0.907,双源双能CT平台AUC为0.893。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of this study is to determine whether iodine quantification techniques from contrast-enhanced dual-energy CT (DECT) data allow equal differentiation of small enhancing renal masses from high-attenuation (> 20 HU of unenhanced attenuation) nonenhancing lesions, compared with conventional attenuation measurements. MATERIALS AND METHODS. A total of 220 nonconsecutive patients (mean [± SD] age, 66 ± 13 years; 130 men and 90 women) with 265 high-attenuation renal lesions (mean attenuation, 54 ± 33 HU; 91 enhancing lesions) were included. Each patient underwent single-energy unenhanced CT followed by DECT during the nephrographic phase using one of four different high-end DECT platforms (first- and second-generation rapid-kilovoltage-switching DECT platforms and second- and third-generation dual-source DECT platforms). Iodine quantification measurements and conventional attenuation change measurements were calculated for each lesion. Diagnostic accuracy was determined by pathologic analysis, confirmation with another imaging modality, or greater than 24 months of imaging follow-up as the reference standard. RESULTS. The diagnostic accuracy for differentiating enhancing from nonenhancing renal lesions was significantly higher for conventional attenuation change measurements, compared with iodine quantification measurements (AUC values, 0.973 vs 0.875; p < 0.0001). The diagnostic performance of iodine quantification measurements improved only marginally with the utilization of DECT platform-specific optimized iodine quantification thresholds, yielding AUC values of 0.907 and 0.893 for the rapid-kilovoltage-switching DECT and dual-source DECT platforms, respectively. Unenhanced lesion attenuation (p = 0.0010) and intraparenchymal location (p = 0.0249) significantly influenced the diagnostic accuracy of the iodine quantification techniques. CONCLUSION. Iodine quantification from DECT data yields inferior diagnostic accuracy when compared with conventional attenuation change measurements for differentiating small, truly enhancing renal masses and high-attenuation renal lesions.
引用
- Meyer M, Nelson RC, Vernuccio F, et al. Comparison of Iodine Quantification and Conventional Attenuation Measurements for Differentiating Small, Truly Enhancing Renal Masses From High-Attenuation Nonenhancing Renal Lesions With Dual-Energy CT. AJR Am J Roentgenol. 2019. PMID: 30917024. doi:10.2214/AJR.18.20547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。